BIOGRAPHICAL SKETCH
Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. DO NOT EXCEED FOUR PAGES.
NAME
POSITION TITLE
Andrew Berchuck
F Bayard Carter Distinguished Professor
Gynecologic Oncology
eRA COMMONS USER NAME
Berch001
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
Case Western Reserve, Cleveland, Ohio
Case Western Reserve, Cleveland, Ohio
Case Western Reserve, Cleveland, Ohio
University of Texas Southwestern, Dallas, Texas
Memorial Sloan Kettering Cancer Center, NY, NY
DEGREE
(if applicable)
BA
MD
MM/YY
6/76
6/80
6/84
6/85
6/87
FIELD OF STUDY
Natural Sciences
Medicine
Obstetrics/Gynecology
Research Fellowship
Gynecologic Oncology
A. PERSONAL STATEMENT
For the past 24 years at Duke University, I have been actively involved in caring for women with gynecologic
cancers on a daily basis while also leading a nationally recognized program in translational ovarian cancer
research. One of my primary areas of current interest is the use of microarrays to develop gene signatures
predictive of outcome as well as to identify potential therapeutic targets in ovarian cancer. I am also director of
the Duke Division of Gynecologic Oncology, which is involved in a wide range of clinical trials in ovarian cancer
including cooperative trials of the Gynecologic Oncology Group (GOG). In addition, I am a leader of the North
Carolina Ovarian Cancer Study, a molecular epidemiologic study that seeks to identify genetic polymorphisms
that affect ovarian cancer susceptibility. I also serve as the head of the Ovarian Cancer Association
Consortium, an international group of 40 studies working together to validate the results of genetic association
studies in ovarian cancer. I also chaired a study section for the Department of Defense Ovarian Cancer
Research Program and led the scientific advisory committee of the Ovarian Cancer Research Fund in New
York City for eight years. My research group houses a large ovarian cancer specimen bank dating back to
1985 that includes fresh frozen tumors, germline DNA, serum and ascites. This bank has been used
successfully in translational research projects both within Duke as well as for multi-institutional and national
research collaborations such as the Cancer Genome Atlas Project.
B. POSITIONS AND HONORS
Positions and Employment
1987 Assistant Professor, Dept. of Obstetrics and Gynecology, Div. of Gynecologic Oncology, Duke University,
1992 Associate Professor, Duke University
1997- Professor with tenure, Duke University
2001- F. Bayard Carter Distinguished Professor, Duke University
2005- Director, Division of Gynecologic Oncology, Duke University
National Service and Awards
1988 American Gynecological and Obstetrical Society, Physician-Scientist Award
1990 American Cancer Society, Clinical Oncology Career Development Award
1992 First Award, NCI R21, “Growth Regulation and Transformation of Ovarian Epithelium”
1994 Wayne Rundles Award for Excellence in Cancer Research, Duke University Cancer Center
1997 President’s award for best plenary presentation, Society of Gynecologic Oncologists
1998 Editorial board, Gynecologic Oncology and Journal of the Society for Gynecologic Investigation
2001 Program Chair, 2001 Annual meeting of the Society of Gynecologic Oncologists
2002 Council member, Society for Gynecologic Investigation
2003 Chair, Scientific Advisory Committee, Ovarian Cancer Research Fund
2004 First prize plenary paper, International Gynecologic Cancer Society meeting
2005 Barbara Thomason Ovarian Cancer Professorship, American Cancer Society
2006 Head, Steering Committee, Ovarian Cancer Association Consortium
2007
2010
President, Society of Gynecologic Oncologists
Nominating Committee, International Gynecologic Cancer Society
C. SELECTED PEER-REVIEWED PUBLICATIONS: (selected from 285)
1. Wenham RM, Schildkraut JM, McLean K, Calingaert B, Bentley RC, Marks J, Berchuck A. Polymorphisms
in BRCA1 and BRCA2 and risk of ovarian cancer. Clin Cancer Res 2003;9:4396-4403. PMID 14555511.
2. Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, Marks JR. Prediction of
optimal versus suboptimal cytoreduction of advanced stage serous ovarian cancer using microarrays Am J
Obstet Gynecol 2004 190:910-25. PMID: 15118612.
3. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, West M, Nevins
JR, Marks JR. Patterns of gene expression that characterize long-term survival in advanced stage serous
ovarian cancers. Clin Cancer Res 2005;15:3686-96. PMID: 15897565.
4. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A,
Olson JA, Marks JR, Dressman HK, West M, Nevins JR. Signatures of oncogenic pathway activation in
human cancers - A guide for use of targeted therapies. Nature 2006;439:353-7. PMID: 16273092.
5. Murphy, SK, Huang, Z, Wen, Y, Spillman, MA, Whitaker, RS, Nichols, TB, Marks, J, and A Berchuck.
Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian
cancer. Mol Cancer Res 2006; 4:283-292. PMID: 16603642.
6. Schildkraut JM, Murphy SK, Palmieri RT, Iversen E, Moorman PG, Huang Z, Halabi S, Calingaert B,
Gusberg A, Marks J, Berchuck A. Trinucleotide repeat polymorphisms in the androgen receptor gene and
risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16:473-80. PMID: 17372243.
7. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke JP, Whitaker R, Li LH, Gray
J, Marks J, Ginsburg G, Potti A, West M, Nevins J, Lancaster JM. An integrated genomic-based approach
to personalized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517-25.
PMID: 17290060.
8. Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd JA, Alonso MA, Secord AA,
Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, Lancaster JM. Microarray
analysis of early stage serous ovarian cancers demonstrates profiles predictive of favorable outcome. Clin
Cancer Res 2009;15:2448-55. PMID: 19318476.
9. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii
S, Marks JR, Berchuck A, Murphy SK. Epigenetic regulation of CD133 and tumorigenicity of CD133+
ovarian cancer cells. Oncogene 2009;28:209-18. PMID: 18836486.
10. Lee, PS, Teaberry, VS, Bland, AE, Huang, Z, Whitaker, RS, Baba, T, Fujii, S, Secord, AA, Berchuck, A,
Murphy, SK. 2009. Elevated MAL expression is accompanied by promoter hypomethylation and poor
prognosis in epithelial ovarian cancer. Int J Cancer 2009; 126:1378-1389. PMID: 20202385.
11. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J,
Cramer DW, DiCioccio R, Dörk T, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L,
Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen Z, Cunningham JM, Dicks E,
Doherty JA, Dürst M, Ekici AB, Fenstermacher D, Fridley BL, Giles G, Gore ME, De Vivo I, Hillemanns P,
Hogdall C, Hogdall E, Iversen ES, Jacobs IJ, Jakubowska A, Li D, Lissowska J, Lubiński J, Lurie G,
McGuire V, McLaughlin J, Medrek K, Moorman PG, Moysich K, Narod S, Phelan C, Pye C, Risch H,
Runnebaum IB, Severi G, Southey M, Stram DO, Thiel FC, Terry KL, Tsai YY, Tworoger SS, Van Den
Berg DJ, Vierkant RA, Wang-Gohrke S, Webb PM, Wilkens LR, Wu AH, Yang H, Brewster W, Ziogas A;
Australian Cancer (Ovarian) Study; Australian Ovarian Cancer Study Group; Ovarian Cancer Association
Consortium, Houlston R, Tomlinson I, Whittemore AS, Rossing MA, Ponder BA, Pearce CL, Ness RB,
Menon U, Kjaer SK, Gronwald J, Garcia-Closas M, Fasching PA, Easton DF, Chenevix-Trench G,
Berchuck A, Pharoah PD, Gayther SA.. A genome-wide association study identifies a novel ovarian cancer
susceptibility locus on 9p22.2. Nat Genet. 2009;41:996-1000. PMID: 19648919.
12. Bernardini MQ, Baba T, Lee PS, Barnett JC, Sfakianos GP, Alvarez Secord A, Murphy SK, Iversen E,
Marks JR, Berchuck A. Expression signatures of TP53 mutations in serous ovarian cancers. BMC
Cancer 2010;10(1):237. PMID: 20504346.
13. Matsumura N, Huang Z, Mori S, Baba T, Fujii S, Konishi I, Iversen ES, Berchuck A, Murphy SK.
Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer.
Genome Res 2011;21:74-82. PMID: 21720365.
14. Teoh D, Ayeni TA, Rubatt JM, Adams DJ, Grace L, Starr MD, Barry WT, Berchuck A, Murphy SK, Secord
AA. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
Gynecol Oncol. 2011;121:187-92. PMID: 21208651
15. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature
2011;474:609-15. PMID: 21720365.
D. RESEARCH SUPPORT
ACTIVE
SIOP-06-090-06 (Berchuck)
01/01/11-12/31/15
American Cancer Society, Inc
Barbara Thomason Ovarian Cancer Professorship
The goal is to identify genetic polymorphisms that affect ovarian cancer susceptibility and to perform
microarray analysis of ovarian cancers to identify patterns of gene expression predictive of outcome and
response to cytotoxic and biological therapies.
TriPath Oncology Inc. (Havrilesky)
7/01/07-06/30/16
Biomarkers in Abnormal Pelvic Mass in Ovarian Cancer Patients
The purpose of this study is to determine the clinical utility of a panel of ovarian cancer markers in
distinguishing malignant from benign pelvic masses using preoperative serum samples from patients
undergoing surgical evaluation for an abnormal pelvic mass.
Role: Co Investigator
5 R01-CA076016-12 (Schildkraut)
08/05/09-06/30/12
National Institutes of Health
The Molecular Epidemiology of Ovarian Cancer
Using DNA samples from ~7000 women with ovarian cancer and 7000 unaffected women, this study will
comprehensively examine variants in more than 150 genes involved in DNA repair to determine if they
increase risk for ovarian cancer, in order to provide insight into biological pathways with prevention potential.
Role: Co Investigator
OCRF-PPD/DUMC.05 (Berchuck)
11/01/09-10/31/12
Ovarian Cancer Research Fund, Inc.
Ovarian Cancer Association Consortium
Continues the activities of the ovarian cancer association consortium (OCAC), a group dedicated to working
together to identify and validate common low penetrance ovarian cancer susceptibility polymorphisms.
W81XWH-09-1-0265 (Blobe)
06/15/09 – 06/14/12
Department of Defense
Role of the Tumor Suppressor TBRIII/betaglycan in Regulating Directional Migration and Polarity in Ovarian
Cancer
Aim 1: To determine whether cell surface TBRII reduces the migration of ovarian epithelial and EOC’s by
disrupting directional migration in a low density culture model for metastatic populations. Aim 2: To determine
whether cell surface TBRIII disrupts the polarity of epithelial and EOC’s and fibroblast cells in a high density
model to study the effect of TBRIII on collective cell motility. Aim 3: to determine the role of TBRIII on
mediating cell-cell adhesion and cell-extracellular matrix (ECM) adhesion in ovarian epithelial derived cancer
cells and stromal cells.
Role: Co-Mentor
5 P30-CA014236-37 (Lyerly)
09/30/10-12/31/14
NIH/NCI
Comprehensive Cancer Center Core Grant
Program Leaders
The mission of the Duke Comprehensive Cancer Center (DCCC) is to make preeminent contributions to
understanding, preventing, detecting, diagnosing and treating cancer through laboratory investigation, clinical
research, cancer prevention and control, research, patient care, education and interaction with individuals and
organizations outside the University.
Roles: Co-Program Leader
5R01-CA142081-02 (Schildkraut)
06/01/10 – 04/30/15
NIH/NCI
Epidemiology of Ovarian Cancer in African American Women
Goals: 1. Establish infrastructure to recruit 1000 African-American women with invasive epithelial ovarian
cancer and an equal number of age-matched controls. 2. Determine how risk factors for ovarian cancer in
African-American women are similar to or differ from established risk factors for white women. 3. Evaluate
genetic risk factors, focusing on concordance or discordance of results with genes that have been reported to
be associated with ovarian cancer in white women in studies from large consortia or GWAS. 4. Obtain
information on treatment and outcome for ovarian cancer cases in African American women.
Role: Co Investigator
HHSN261201000019I (Berchuck)
05/20/10 – 05/04/12
National Institutes of Health
Endometrial Cancer TCGA Project
This project covers supports the collection, processing, storage and sharing of endometrial cancer specimens
for the Cancer Genome Atlas Project.
2U01-CA084955-12 (Marks)
09/01/10-06/30/15
National Institutes of Health
Atlantic Breast and Gynecologic Clinical Validation Center
Specific Aim: Compare promising biomarkers for their utility in specific clinical applications for breast, ovarian
and cervical cancer.
Role: Co Investigator
W81XWH-11-1-0469 (Murphy)
09/30/11-9/29/13
Department of Defense
Preemptive Approach to Improving Survival in Epithelial Ovarian Cancer
Objective: to determine if drugs that we have identified as being able to more effectively target slow
proliferating cells in vitro can be used to reduce the incidence of persistent or recurrent disease using a mouse
xenograft model of epithelial ovarian cancer.
Role: Co Investigator
5U19-CA148112-02 (Schildkraut)
07/02/10-06/30/14
H. Lee Moffitt Cancer Center & Research Institute
Ovarian Cancer Post GWAS
Specific aims are 1) to evaluate gene-gene interactions of SNP associations using the Ovarian Cancer GWAS;
2) to evaluate gene-environment interactions based on findings of the Ovarian Cancer GWAS; 3) to create a
model predicting ovarian cancer risk based on the evaluation of genetic and environmental factors in Aims 1
and 2.
Role: Co Investigator
5R01-CA122443-05 (Berchuck)
Mayo Clinic
Genetic Variation in the NFKB Pathway and Ovarian Cancer Etiology
08/01/11-07/31/12
This study is a continuation of the North Carolina Ovarian Cancer Study (NCOCS), a molecular
epidemiologic study of primary epithelial ovarian cancer. The central goal of the NCOCS is to define
subsets of epithelial ovarian cancer based on genetic susceptibility, specific disease causing
exposure, acquired molecular alterations, and clinicopathologic features.
COMPLETED (abbreviated)
29XS120 (Berchuck)
04/17/09-01/15/10
SAIC-Frederick, Inc
Cancer Genome Atlas (TCGA) Pilot Program
The Cancer Genome Atlas (TCGA) Pilot Program is a comprehensive and coordinated three year effort,
funded by the NCI and NHGRI, to accelerate understanding of the molecular basis of cancer through the
application of genomic analysis technologies, including large-scale genome sequencing.